Research Collaboration Aims to Bring TLR9 Agonist SD-101 to Patients With Pancreatic and Liver Cancer
OncLive,
The initial study of the collaboration will enroll patients with uveal melanoma–related liver metastases, with other studies…
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
Overview of attention for article published in Journal of Clinical Oncology, May 2019
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (74th percentile)
-
Above-average Attention Score compared to outputs of the same age and source (51st percentile)
Readers on
- mendeley
- 8 Mendeley